Impact of Genetic Mutations on MDS Risk Assessment and Treatment

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: October 30, 2017
Expiration Date: October 30, 2018

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

The molecular profile of MDS has become a vital factor in assessing the risk of patients with MDS and making treatment decisions. Health care providers must understand when to order genetic testing, how to interpret the results, and the implications of specific cytogenetic abnormalities on the Revised International Prognostic Scoring System (IPSS-R). In addition, the genetic profile of a patient’s disease may dictate which therapy is most appropriate. In this activity, participants will learn about genetic mutations that dictate treatment selection, as well as investigational therapies for specific cytogenetic abnormalities in MDS.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Outline the risk of patients with MDS based on their cytogenetic profile and IPSS-R risk category
  • Describe the impact of genetic mutations on current treatment paradigms and drug selection
  • Recognize therapies under investigation in clinical trials for specific cytogenetic abnormalities


Impact of Genetic Mutations on MDS Risk Assessment and Treatment – Rafael Bejar, MD, PhD

Instructions for Participation and Credit

This activity is eligible for credit through October 30, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Rafael Bejar, MD, PhD
UC San Diego Health
Moores Cancer Center
La Jolla, California

Dr. Rafael Bejar received his medical and PhD degrees in the Medical Scientist Training Program at University of California, San Diego (UCSD) prior to his medical internship at the University of Chicago. He completed his residency in internal medicine at the Brigham and Women’s Hospital in Boston where he later served as a chief medical resident. Dr. Bejar then served as fellow in hematology and oncology at the Dana-Farber Cancer Institute where he later became an instructor and worked in the laboratory of Dr. Benjamin Ebert on the genetic basis of MDS. He is currently a physician-scientist at the UC San Diego Health Moores Cancer Center in La Jolla, California, where his laboratory studies the molecular basis of myelodysplastic syndromes (MDS) and related neoplasms.

Dr. Bejar serves on the molecular prognosis committee of the International Working Group for MDS and is a member of the NCCN Clinical Guidelines Committee for MDS. At UCSD, he has established an MDS Center of Excellence where he cares for patients, oversees clinical trials, and continues to study the molecular mechanisms that drive the development of MDS.

In collaboration with several groups, Dr. Bejar’s work has helped identify how genetic mutations contribute to the development of MDS and how testing for these abnormalities can help physicians care for their patients with this disease (New England Journal of Medicine, 2011). Most recently, he has published on mutations that predict response to treatment with hypomethylating agents (Blood, 2014) and outcomes after stem cell transplantation (Journal of Clinical Oncology, 2014). His laboratory is now focused on the role of somatic mutations in splicing factors and epigenetic regulators in MDS.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-174-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Rafael Bejar has received honoraria as a consultant from AbbVie Inc., Astex Pharmaceuticals, Celgene Corporation, Foundation Medicine, Inc., Genentech, Inc., Genoptix–a Novartis Company, and Otsuka Pharmaceutical Co., Ltd. He has received grant support related to research activities from Celgene and Takeda Oncology. He has also received royalties or licensing fees from Genoptix.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.